Damora Therapeutics, Inc. (NASDAQ:DMRA) — Market Cap & Net Worth
Market Cap & Net Worth: Damora Therapeutics, Inc. (DMRA)
Damora Therapeutics, Inc. (NASDAQ:DMRA) has a market capitalization of $1.30 Billion ($1.30 Billion) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7751 globally and #2300 in its home market, demonstrating a 4.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Damora Therapeutics, Inc.'s stock price $21.08 by its total outstanding shares 61735519 (61.74 Million).
Damora Therapeutics, Inc. Market Cap History: 2026 to 2026
Damora Therapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $1.30 Billion to $1.30 Billion (0.00% CAGR). Check DMRA share price today for real-time trading data and today's change.
Damora Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Damora Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see how efficiently does Damora Therapeutics, Inc. generate cash for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DMRA by Market Capitalization
Companies near Damora Therapeutics, Inc. in the global market cap rankings as of October 10, 2026. See DMRA equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to Damora Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Damora Therapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Damora Therapeutics, Inc.'s market cap moved from $1.30 Billion to $ 1.30 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Damora Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.30 Billion USD |
| MoneyControl | $1.30 Billion USD |
| MarketWatch | $1.30 Billion USD |
| marketcap.company | $1.30 Billion USD |
| Reuters | $1.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more